Rebound of COVID-19 symptoms rare after nirmatrelvir/ritonavir treatment
Jun 16, 2022
Only 0.8% of 483 patients with mild-to-moderate SARS-CoV-2 at high risk for severe disease progression had rebound.
Fauci tests positive for COVID-19, has mild symptoms
Jun 16, 2022
The infectious disease specialist is fully vaccinated and has received two booster shots.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Risk for psychiatric illness up in early postacute COVID-19 phase
Jun 14, 2022
Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in the early postacute phase.
Relative risk for CVT up after AZD1222 COVID-19 vaccine
Jun 14, 2022
Relative rates of hospital contacts for coagulation disorder and cerebrovascular disease increased after AZD1222 (Astra Zeneca) vaccination.
Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Older adults more likely to have multiple ailments compared with prior generations
By
Amy Novotney
Jun 14, 2022
Later-born generations of older adults in the United States are more likely to have a greater number of chronic health conditions than the generations that preceded them, according to a study conducted...
Text messaging intervention does not improve COVID-19 vaccine uptake
Jun 13, 2022
No increase in vaccine uptake was seen for individuals receiving text message versus phone calls or for behaviorally informed message content.
Durability of mRNA-1273 protection against symptomatic COVID-19 examined
Jun 13, 2022
Among those receiving two doses of the Moderna vaccine, peak vaccine efficacy against symptomatic COVID-19 was estimated to be 94.1% at 120 days after the first dose.